Basal Insulin: Physiology, Pharmacology, and Clinical Implications

References

• . Thompson R, Christie D, Hindmarsh PC. The role for insulin analogues in diabetes care. Curr Paediatr. 2006;16:117–122
   Google Scholar
• . Bonadonna RC, Stumvoll M, Fritsche A,. Altered homeostatic adaptation of first- and second-phase β-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess β-cell function. Diabetes. 2003;52(2):470–480
   PubMed Web of Science ®Google Scholar
• . Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc. 2009;109(1):26–36
   PubMedGoogle Scholar
• . Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–1686
   PubMed Web of Science ®Google Scholar
• . Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17–20
   PubMed Web of Science ®Google Scholar
• . Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31(10):1927–1932
   PubMed Web of Science ®Google Scholar
• . Dailey G. Optimum management of type 2 diabetes—timely introduction, optimization and intensification of basal insulin. Diabetes Obes Metab. 2008;10( suppl 2):5–13
   PubMed Web of Science ®Google Scholar
• . Gavin JR 3rd, Peragallo-Dittko V, Rodgers PT. A new look at established therapies: practical tools for optimizing insulin use. Diabetes Educ. 2010;36( suppl 2):26S–38S
   Web of Science ®Google Scholar
• . Colagiuri S, Cull CA, Holman RR; UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. Prospective Diabetes Study 61. Diabetes Care. 2002;25(8):1410–1417
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Cleary PA, Backlund JY,; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
   PubMed Web of Science ®Google Scholar
• . Ceriello A. Hypothesis: the “metabolic memory,” the new challenge of diabetes. Diabetes Res Clin Pract. 2009;86( suppl 1):S2–S6
   PubMed Web of Science ®Google Scholar
• . Taubes G. Diabetes: paradoxical effects of tightly controlled blood sugar. Science. 2008;322(5900):365–367
   PubMed Web of Science ®Google Scholar
• . Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008;24(5):353–363
   PubMed Web of Science ®Google Scholar
• . Jensen M, De Meyts P. Molecular mechanisms of differential intracellular signaling from the insulin receptor. Vitam Horm. 2009;80:51–75
   PubMed Web of Science ®Google Scholar
• . Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96
   PubMed Web of Science ®Google Scholar
• . Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab. 2008;295(4):E751–E761
   Web of Science ®Google Scholar
• . Lomberk G, Urrutia R. Primers on molecular pathways—the insulin pathway. Pancreatology. 2009;9(3):203–205
   PubMed Web of Science ®Google Scholar
• . Klover PJ, Mooney RA. Hepatocytes: critical for glucose homeostasis. Int J Biochem Cell Biol. 2004;36(5):753–758
   PubMed Web of Science ®Google Scholar
• . Cherrington AD. The role of hepatic insulin receptors in the regulation of glucose production. J Clin Invest. 2005;115(5):1136–1139
   PubMed Web of Science ®Google Scholar
• . Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010;375(9733):2267–2277
   PubMed Web of Science ®Google Scholar
• . Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463–478
   PubMed Web of Science ®Google Scholar
• . Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129–139
   PubMed Web of Science ®Google Scholar
• . Groop LC, Bonadonna RC, DelPrato S,. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205–213
   PubMed Web of Science ®Google Scholar
• . Kurtzhals P, Schäffer L, Sorensen A,. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005
   PubMed Web of Science ®Google Scholar
• . Sheehan JP. Fasting hyperglycemia: etiology, diagnosis, and treatment. Diabetes Technol Ther. 2004;6(4):525–533
   PubMedGoogle Scholar
• . Nathan DM, Buse JB, Davidson MB,. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA,. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2–3):307–335
   PubMed Web of Science ®Google Scholar
• . Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673–682
   PubMedGoogle Scholar
• . Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174–183
   PubMed Web of Science ®Google Scholar
• . Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet. 2001;358(9283):739–746
   PubMed Web of Science ®Google Scholar
• . Owens DR, Vora JP, Jones IR,. Soluble and Lente human insulin mixtures in normal man. Diabetes Res. 1988;7(1):35–40
   PubMedGoogle Scholar
• . Humulin L Lente human insulin (rDNA origin) zinc suspension [prescribing information]. Indianapolis, IN: Eli Lilly & Co; 2004
   Google Scholar
• . Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188–199
   PubMed Web of Science ®Google Scholar
• . Humulin R (regular U-500 [concentrated] insulin human injection [rDNA origin]) [prescribing information]. Indianapolis, IN: Eli Lilly & Co; 2011
   Google Scholar
• . Dailey AM, Tannock LR. Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep. 2011;11(2):77–82
   PubMed Web of Science ®Google Scholar
• . Lepore M, Pampanelli S, Fanelli C,. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49(12):2142–2148
   PubMed Web of Science ®Google Scholar
• . Fanelli CG, Pampanelli S, Porcellati F, Rossetti P, Brunetti P, Bolli GB. Administration of neutral protamine Hagedorn insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. Ann Intern Med. 2002;136(7):504–514
   PubMed Web of Science ®Google Scholar
• . Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008;10(5):333–349
   PubMed Web of Science ®Google Scholar
• . Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet. 1999;354(9190):1604–1607
   PubMed Web of Science ®Google Scholar
• . Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med. 2002;113(4):308–316
   PubMed Web of Science ®Google Scholar
• . Barnett AH. A review of basal insulins. Diabet Med. 2003;20(11):873–885
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51(3):408–416
   PubMed Web of Science ®Google Scholar
• . King AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab. 2009;11(1):69–71
   PubMed Web of Science ®Google Scholar
• . Barnett AH. Insulin glargine in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag. 2006;2:59–67
   PubMedGoogle Scholar
• . Baxter MA. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Acta Diabetol. 2008;45(4):253–268
   PubMed Web of Science ®Google Scholar
• . Le Roith D. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007;23(8):593–599
   PubMed Web of Science ®Google Scholar
• . Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Häring HU. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res. 1998;30(3):123–129
   PubMed Web of Science ®Google Scholar
• . Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab. 2001;86(12):5838–5847
   PubMed Web of Science ®Google Scholar
• . Bahr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol. 1997;320(2–3):259–265
   PubMed Web of Science ®Google Scholar
• . Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem. 2010;116(2):73–78
   PubMedGoogle Scholar
• . Chaykin LB. Insulin detemir and its unique mechanism of action. Int J Endocrinol. 2007;4(1):e1
   Google Scholar
• . Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab. 2005;31(4 pt 2):4S25–4S33
   PubMed Web of Science ®Google Scholar
• . Havelund S, Plum A, Ribel U,. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21(8):1498–1504
   PubMed Web of Science ®Google Scholar
• . Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9(3):290–299
   PubMed Web of Science ®Google Scholar
• . Heise T, Nosek L, Ronn BB,. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614–1620
   PubMed Web of Science ®Google Scholar
• . Kurtzhals P. Pharmacology of insulin detemir. Endocrinol Metab Clin North Am. 2007;36( suppl 1):14–20
   PubMed Web of Science ®Google Scholar
• . Kurtzhals P, Colding-Jorgensen M. Albumin binding of insulin detemir reduces the risk for hypoglycemic events. Diabetes. 2004;53( suppl 2):A477 (abstract)
   Web of Science ®Google Scholar
• . Kurtzhals P, Havelund S, Jonassen I,. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312(part 3):725–731
   PubMed Web of Science ®Google Scholar
• . Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes. 2004;28( suppl 2):S23–S28
   Web of Science ®Google Scholar
• . Plank J, Bodenlenz M, Sinner F,. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28(5):1107–1112
   PubMed Web of Science ®Google Scholar
• . Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648–659
   PubMed Web of Science ®Google Scholar
• . Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23(6):813–819
   PubMed Web of Science ®Google Scholar
• . Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with type 1 diabetes. Diabet Med. 2002;19(6):490–495
   PubMed Web of Science ®Google Scholar
• . Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care. 2008;14(1):25–30
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28(4):950–955
   PubMed Web of Science ®Google Scholar
• . Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006;7(3):325–343
   PubMed Web of Science ®Google Scholar
• . De Leeuw I, Vague P, Selam JL,. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab. 2005;7:73–82
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269–1274
   PubMed Web of Science ®Google Scholar
• . Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569–1581
   PubMed Web of Science ®Google Scholar
• . Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhnand D, Valentine WJ. Long-acting insulin analogs: a review of “real-world” effectiveness in patients with type 2 diabetes. Curr Diabetes Rev. 2011;7(1):61–74
   PubMedGoogle Scholar
• . Hallschmid M, Jauch-Chara K, Korn O,. Euglycemic infusion of insulin detemir compared to human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes. 2010;59(4):1101–1107
   PubMed Web of Science ®Google Scholar